Well-authenticated biomarkers can provide critical insights into the biological basis of
Alzheimer disease (AD) to enable timely and accurate diagnosis, estimate future burden and …

Background Blood phosphorylated tau (p-tau) forms are promising Alzheimer's disease (AD)
biomarkers, but validation in matrices other than ethylenediaminetetraacetic acid (EDTA) …

As the leading cause of dementia, Alzheimer's disease (AD) is a major burden on affected
individuals, their families and caregivers, and healthcare systems. Although AD can be …

Plasma phospho-tau (p-tau) species have emerged as the most promising blood-based
biomarkers of Alzheimer's disease. Here, we performed a head-to-head comparison of p …

Background Deposition of tau aggregates is a pathological hallmark of Alzheimer's disease
that is closely linked both spatially and temporally to emergence of neurodegeneration and …

Introduction Plasma tau may be an accessible biomarker for Alzheimer's disease (AD), but
the correlation between plasma and cerebrospinal fluid (CSF) tau and the value of …

Discovery and development of clinically useful biomarkers for Alzheimer's disease (AD) and
related dementias have been the focus of recent research efforts. While cerebrospinal fluid …

Brain-derived tau secreted into CSF and blood consists of different N-terminal and mid-
domain fragments, which may have a differential temporal course and thus, biomarker …

Tau phosphorylated at threonine 181 (p-tau181) measured in blood plasma has recently
been proposed as an accessible, scalable, and highly specific biomarker for Alzheimer's …

The quantification of phosphorylated tau in biofluids, either cerebrospinal fluid (CSF) or
plasma, has shown great promise in detecting Alzheimer's disease (AD) pathophysiology …